- Home
- LYRA vs CYCN Comparison
LYRA vs CYCN Comparison
Compare LYRA & CYCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LYRA
- CYCN
- Stock Information
- Founded
- LYRA 2005
- CYCN 2018
- Country
- LYRA United States
- CYCN United States
- Employees
- LYRA N/A
- CYCN N/A
- Industry
- LYRA Medical/Dental Instruments
- CYCN Biotechnology: Pharmaceutical Preparations
- Sector
- LYRA Health Care
- CYCN Health Care
- Exchange
- LYRA Nasdaq
- CYCN Nasdaq
- Market Cap
- LYRA 5.8M
- CYCN 6.5M
- IPO Year
- LYRA 2020
- CYCN N/A
- Fundamental
- Price
- LYRA $24.28
- CYCN $3.18
- Analyst Decision
- LYRA Buy
- CYCN
- Analyst Count
- LYRA 2
- CYCN 0
- Target Price
- LYRA $100.00
- CYCN N/A
- AVG Volume (30 Days)
- LYRA 1.9M
- CYCN 20.7K
- Earning Date
- LYRA 05-06-2025
- CYCN 05-06-2025
- Dividend Yield
- LYRA N/A
- CYCN N/A
- EPS Growth
- LYRA N/A
- CYCN N/A
- EPS
- LYRA N/A
- CYCN N/A
- Revenue
- LYRA $1,185,000.00
- CYCN $2,081,000.00
- Revenue This Year
- LYRA N/A
- CYCN N/A
- Revenue Next Year
- LYRA $1,286.17
- CYCN N/A
- P/E Ratio
- LYRA N/A
- CYCN N/A
- Revenue Growth
- LYRA N/A
- CYCN N/A
- 52 Week Low
- LYRA $3.81
- CYCN $1.27
- 52 Week High
- LYRA $37.50
- CYCN $9.47
- Technical
- Relative Strength Index (RSI)
- LYRA 76.38
- CYCN 53.92
- Support Level
- LYRA $22.22
- CYCN $3.04
- Resistance Level
- LYRA $27.42
- CYCN $3.26
- Average True Range (ATR)
- LYRA 4.12
- CYCN 0.25
- MACD
- LYRA 2.36
- CYCN 0.01
- Stochastic Oscillator
- LYRA 60.76
- CYCN 80.00
About LYRA Lyra Therapeutics Inc.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.
About CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.